Skip to main content

Table 2 Factors associated with subsequent CRE infection among hematological malignancies patients colonized with CRE

From: Prevalence and factors associated with carbapenem-resistant Enterobacterales (CRE) infection among hematological malignancies patients with CRE intestinal colonization

Variables

Case group (N = 18)

Control group (N = 36)

P-value

Demographics

   

Age (Median, IQR)

38.5 (19–54.5)

40 (20–54.5)

 

Sex, male

10 (55.6)

20 (55.6)

 

Hospitalization

   

Length of stay, (IQR,days)

52.5 (30.5–80.5)

49.0 (21.0–91.0)

0.783

Transferring from another hospital

3 (16.7)

8 (22.2)

0.905

Admission to ICU

6 (33.3)

2 (5.6)

0.021*

Prior hospitalization

13 (72.2)

23 (63.9)

0.540

Comobidity conditions

   

Diabetes mellitus

2 (11.1)

3 (8.3)

1.000

Solid tumor

2 (11.1)

2 (5.6)

0.854

Pneumonia

14 (77.8)

18 (50.0)

0.050

Liver disease

9 (50.0)

10 (27.8)

0.107

Gastritis

4 (22.2)

2 (5.6)

0.168

Shock

8 (44.4)

9 (25.0)

0.147

Diarrhea

13 (72.2)

13 (36.1)

0.012*

 

7 (38.9)

10 (27.8)

0.407

Invasive procedures

   

Central venous catheter

14 (77.8)

30 (83.3)

0.901

Arterial catheter

4 (22.2)

2 (5.6)

0.168

Endotracheal intubation

2 (11.1)

3 (8.3)

1.000

Mechanical ventilation

10 (55.6)

8 (22.2)

0.014*

Urinary catheter

4 (22.2)

2 (5.6)

0.168

Nasogastric tube

4 (22.2)

1 (2.8)

0.068

HSCT

5 (27.8)

15 (41.7)

0.319

Drug exposure

   

PPIs

15 (83.3)

18 (50.0)

0.018*

Glucocorticoid

13 (72.2)

19 (52.8)

0.170

Cephalosporins

6 (33.3)

4 (11.1)

0.107

Carbapenems

17 (94.4)

26 (72.2)

0.120

Fluoroquinolones

9 (50.0)

19 (52.8)

0.847

Glycopeptides

9 (50.0)

16 (44.4)

0.700

Tigecycline

8 (44.4)

11 (30.6)

0.314

Oxazolidones

6 (33.3)

10 (27.8)

0.673

Aminoglycosides

3 (16.7)

7 (19.4)

1.000

β-lactam/β-lactamase inhibitors

12 (66.7)

21 (58.3)

0.554

Macrolides

2 (11.1)

4 (11.1)

1.000

Antifungal agents

14 (77.8)

31 (86.1)

0.699

Antiviral agents

7 (38.9)

17 (47.2)

0.561

CRE isolates

   

Klebsiella pneumoniae

10 (55.6)

17 (47.2)

0.564

Escherichia coli

6 (33.3)

9 (25.0)

0.519

Enterobacter cloacae

1 (5.6)

4 (11.1)

0.868

others

1 (5.6)

6(2.8)

0.64

Types of hematological malignancy

   

AML

8 (44.4)

18 (50.0)

0.700

ALL

6 (33.3)

7 (19.4)

0.260

MM

0 (0.0)

2 (5.6)

0.313

Lymphoma

4 (22.2)

7 (19.4)

1.000

others

0 (0.0)

2 (5.6)

0.313

  1. Values are presented as n(%), unless otherwise noted
  2. OR, odds ration; CI, confidence interval; IQR, Interquartile range; ICU, intensive care unit; CRE, Carbapenem-resistant Enterobacterales; HSCT, hematopoietic stem cell transplantation; PPI, proton pump inhibitors; TMP/SMX, sulfamethoxazole and trimethoprim.; AML, Acute Myeloid Leukemia; ALL, Acute Lymphoblastic Leukemia; MM,Multiple Myeloma
  3. * Statistically significant differences between groups (P < 0.05)
Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us